Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX

By Lyseng-Williamson Katherine A.   Plosker Greg L.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1007-1029

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Coagulation Factors: Clinical Relevance for Patients with Haemophilia

By Björkman S.   Berntorp E.  

Clinical Pharmacokinetics, Vol. 40, Iss. 11, 2001-01 ,pp. : 815-832

Adis International

Access to resources Recommend Favorite

Economic and Epidemiological Modelling of Full-Length Antihaemophilic Factor (Recombinant), Plasma/Albumin-Free Method, in Previously Treated Patients with Haemophilia A: Comparison with B-Domain Deleted rFVIII, and Value of Potential Viral Transmission Reduction due to Plasma/Albumin-Free Status

By Sclar David A.   Evans Marc A.   Skaer Tracy L.   Robison Linda M.   Chung Karen C.   Poulios Nick S.  

Drugs in R&D, Vol. 6, Iss. 3, 2005-01 ,pp. : 149-156

Adis International

Access to resources Recommend Favorite

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

By  

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Determinants of Drug Costs in Hospitalised Patients with Haemophilia: Impact of Recombinant Activated Factor VII

By Galanaud J.P.  

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 699-707

Adis International

Access to resources Recommend Favorite